吉西他滨预处理后胰腺癌二线奥沙利铂或伊立替康化疗的系统评价
该系统评价纳入24项研究,比较吉西他滨一线治疗后转移性胰腺癌患者接受奥沙利铂或伊立替康联合氟嘧啶类二线化疗的疗效。汇总客观缓解率11%、疾病控制率37.9%、中位无进展生存期2.87个月、中位总生存期5.48个月;两组缓解率、无进展生存期和总生存期无显著差异,奥沙利铂组疾病控制率更高(41.1% vs 29.4%,卡方P=0.0008)。
要点
- 汇总客观缓解率11%,疾病控制率37.9%,中位无进展生存期2.87个月,中位总生存期5.48个月。
- 奥沙利铂组与伊立替康组缓解率无显著差异(11.9% vs 8.7%,卡方P=0.1)。
- 奥沙利铂组疾病控制率高于伊立替康组(41.1% vs 29.4%,卡方P=0.0008)。
核心结论
- 在吉西他滨治疗后晚期胰腺癌患者中,含奥沙利铂方案与含伊立替康方案疗效相似。
研究设计与样本
- 系统评价纳入24项已发表研究,对象为接受奥沙利铂或伊立替康联合氟嘧啶类化疗的IV期胰腺癌患者。
主要发现
- 汇总客观缓解率11%,疾病控制率37.9%,中位无进展生存期2.87个月,中位总生存期5.48个月。
- 奥沙利铂组与伊立替康组缓解率无显著差异(11.9% vs 8.7%,卡方P=0.1)。
- 奥沙利铂组与伊立替康组中位无进展生存期无显著差异(2.9个月 vs 2.7个月,t检验P=0.72)。
- 奥沙利铂组与伊立替康组中位总生存期无显著差异(5.3个月 vs 5.5个月,t检验P=0.72)。
- 奥沙利铂组疾病控制率高于伊立替康组(41.1% vs 29.4%,卡方P=0.0008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: oxaliplatin (OXA)- and irinotecan (IRI)-based chemotherapies are the most frequently used salvage regimens in patients with metastatic pancreatic cancer (PC) after first-line gemcitabine-based therapy. There are no prospective comparisons of these regimens in this setting. We conducted a systematic review of published trials to compare the efficacy of these treatments. METHODS: studies that enrolled patients with stage IV disease receiving chemotherapy with OXA or IRI plus fluoropyrimidines were identified using electronic databases (Pubmed, Embase, SCOPUS, CINAHL, Web of Science and Cochrane Library). Clinical outcomes were compared using weighted values of median overall survival (OS), progression-free survival (PFS), response rates (RRs), and clinical benefit rates (CBRs). A 2-tailed t-test with a significance level of 0.05 for comparisons of continuous variables and a Chi-squared test for comparisons of proportions were used. RESULTS: overall, 24 studies were included. The pooled overall response rate (ORR), disease control rate (DCR), PFS and OS were 11%, 37.9%, 2.87 and 5.48 months respectively. There was no significant difference in response rates between OXA-based and IRI-based chemotherapies (11.9% versus 8.7%; Chi-squared P = 0.1), respectively. Also there was no significant difference in median PFS (2.9 months versus 2.7 months; t-test P = 0.72), OS (5.3 months versus 5.5 months; t-test P = 0.72), but a greater DCR with OXA-based chemotherapy (41.1% versus 29.4%; Chi-squared P = 0.0008). CONCLUSION: OXA- and IRI-containing regimens were associated with similar efficacy when used after gemcitabine-based chemotherapy in patients with advanced pancreatic cancer.
引用
- Petrelli F, Inno A, Ghidini A, et al. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Eur J Cancer. 2017. PMID: 28633088. doi:10.1016/j.ejca.2017.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。